ORYZON cierra su ronda de financiación y capta 27 millones de euros

by Oryzon Genomics

Oryzon acaba de cerrar varios préstamos a largo plazo con distintas entidades bancarias por un importe total de 10,5 millones de euros. Con la suscripción de dichos préstamos se da por finalizada l...

Read more

Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease

by Oryzon Genomics

Epigenetic approaches to modify the progression of various neurodegenerative diseases focus on producing changes in patterns of gene expression in neurons and also in glia cells and are of interest fo...

Read more

Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors

by Oryzon Genomics

Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced that the company was granted two unsecured...

Read more

Oryzon raises $ 19 Million in Private Placement to Advance Therapeutic Programs

by Oryzon Genomics

Carlos Buesa, Oryzon’s Co-Founder, President and Chief Executive Officer commented, " The success of this capital raise is affirmation that investors , some of them specialized in the epigenetics fi...

Read more

Interview to Carlos Buesa: The future lies in frontier science

by Oryzon Genomics

The agreement between Oryzon Genomics and Roche, a company specializing in developing oncology drugs, encompasses researching, developing and marketing inhibitors of LSD1 for oncology, hematology and ...

Read more

Roche and Oryzon announce collaboration to develop epigenetics-based medicines

by Oryzon Genomics

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Oryzon Genomics SA today announced they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethyl...

Read more

ORYZON receives approval from MHRA to initiate Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia in the United Kingdom

by Oryzon Genomics

he First Specific LSD1 Inhibitor to Enter the Clinic. Barcelona, Spain. January 16th, 2014. ORYZON, a biopharmaceutical company with a strong focus on epigenetics, hasannounced that has receiv...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Identifican nuevos mecanismos implicados...

by CIMA - Centro de Investigación Médica Aplicada

Investigadores del Cima y de la Clínica Universidad de Navarra confir...

Photos Stream